Leeward Investments LLC MA Lowers Position in Envista Holdings Co. (NYSE:NVST)

Leeward Investments LLC MA lowered its holdings in Envista Holdings Co. (NYSE:NVST) by 1.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 636,627 shares of the company’s stock after selling 10,948 shares during the period. Leeward Investments LLC MA’s holdings in Envista were worth $15,317,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. River Road Asset Management LLC bought a new stake in shares of Envista during the fourth quarter valued at approximately $54,931,000. The Manufacturers Life Insurance Company boosted its position in shares of Envista by 512.7% during the third quarter. The Manufacturers Life Insurance Company now owns 750,125 shares of the company’s stock valued at $20,913,000 after purchasing an additional 627,686 shares in the last quarter. DAVENPORT & Co LLC bought a new stake in shares of Envista during the fourth quarter valued at approximately $13,233,000. Paradice Investment Management LLC boosted its position in shares of Envista by 54.1% during the third quarter. Paradice Investment Management LLC now owns 1,308,983 shares of the company’s stock valued at $36,494,000 after purchasing an additional 459,706 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Envista by 208.4% during the third quarter. AQR Capital Management LLC now owns 645,718 shares of the company’s stock valued at $18,003,000 after purchasing an additional 436,343 shares in the last quarter.

Envista Stock Up 1.8 %

Shares of NYSE:NVST opened at $20.39 on Friday. The company has a quick ratio of 1.90, a current ratio of 2.23 and a debt-to-equity ratio of 0.33. Envista Holdings Co. has a 1 year low of $18.95 and a 1 year high of $38.68. The stock’s fifty day moving average price is $20.95 and its 200-day moving average price is $22.72.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). Envista had a negative net margin of 3.90% and a positive return on equity of 6.31%. The business had revenue of $645.60 million for the quarter, compared to the consensus estimate of $638.37 million. During the same period in the previous year, the company earned $0.52 earnings per share. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. As a group, research analysts anticipate that Envista Holdings Co. will post 1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NVST. Morgan Stanley lowered Envista from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $33.00 to $21.00 in a research report on Friday. TheStreet downgraded Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th. SVB Leerink initiated coverage on Envista in a report on Monday, February 26th. They issued an “underperform” rating and a $19.00 target price on the stock. Leerink Partnrs reissued an “underperform” rating on shares of Envista in a report on Monday, February 26th. Finally, William Blair downgraded Envista from an “outperform” rating to a “market perform” rating in a report on Thursday, February 8th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Envista currently has a consensus rating of “Hold” and a consensus target price of $27.90.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.